共查询到19条相似文献,搜索用时 86 毫秒
1.
目的探讨妇女绝经后骨质疏松病人治疗的常用方法及治疗效果。方法搜集从2008年7月—2011年6月来该院治疗的被诊断为骨质疏松的绝经期后妇女病人共141例,并将其分成ABC三组,对A组的46例病人给予600mg钙尔奇D3片与0.25μg的骨化三醇胶丸,对于B组的42例在钙尔奇D3与骨化三醇治疗基础之上再给予50IU的鲑鱼降钙素,对于C组病人53例在钙尔奇D3与骨化三醇治疗的基础上,再给予3mg的伊班膦酸钠进行静脉滴注,并分别在基线与12个月以后记录下骨密度和SF-36量表评价的生活质量并进行VAS的疼痛评分。结果 A组病人在骨密度和疼痛以及生活质量评分方面都略有好转,但是和基线相比差异无统计学意义;B组病人在骨密度和疼痛及生活质量评分方面都存在较大改善,其和基线相比差异有统计学意义;对于C组病人,在以上指标都有了明显的改善,和基线相比差异有统计学意义。结论对于妇女绝经后骨质疏松的治疗,应当联合用药,仅仅依靠钙剂与活性维生素D3的补充,无法有效地提高骨密度;而伊班膦酸钠静脉注射由于使用起来比较方便,其增加骨密度的效果也非常好,所以属于当前治疗妇女绝经后骨质疏松的最为理想的药物。 相似文献
2.
目的:比较注射型唑来膦酸盐与鲑鱼降钙素治疗绝经后骨质疏松疗效的临床疗效。方法:将71名绝经后骨质疏松患者给予补充钙剂及维生素D的常规治疗,随机分为唑来膦酸组(34例)及鲑鱼降钙素组(37例)。分别给予唑来膦酸注射液(密固达)5 mg/100 mL共一次,或鲑鱼降钙素隔日肌内注射50 U,连续使用1月后改为,50 U 1次/周,连续使用6个月,对比其疗效。结果:唑来膦酸在缓解骨痛,增加骨密度,减少骨折发生率方面都有一定效果,在半年的观测骨痛缓解及骨密度增加和降钙素组相似,12个月后的观测,缓解骨痛更加明显(P<0.05)。结论:唑来膦酸注射液对绝经后骨质疏松症患者具有缓解骨痛增加骨密度提高生活质量减少骨折发生的作用,是一种有效安全的药物。 相似文献
3.
鲑鱼降钙素鼻喷剂治疗绝经后骨质疏松疗效观察 总被引:2,自引:0,他引:2
目的观察鲑鱼降钙素治疗对绝经后骨质疏松症骨密度的影响.方法收集98例绝经后妇女,应用鲑鱼降钙素治疗78例绝经后骨质疏松症患者12周,A组24人鼻喷鲑鱼降钙素,B组54人每天肌注鲑鱼降钙素,两组均加服钙剂,C组20人单独服用钙剂(2 g/d).观察治疗前后腰椎骨密度的变化.结果两治疗组L1~4骨密度在治疗前后差异均有显著性,C组各观察指标无明显变化.结论鲑鱼降钙素鼻喷剂治疗绝经后骨质疏松症可提高骨密度,改善骨代谢. 相似文献
4.
《吉林医学》2016,(7)
目的:探讨针灸结合阿仑膦酸钠治疗绝经后骨质疏松症的疗效。方法:40例绝经后骨质疏松症患者随机分为治疗组和对照组各20例,均给予钙剂(钙尔奇600 mg/d)、骨化三醇(罗盖全)0.25 ug/d及阿仑膦酸钠(福善美)70 mg/周口服,治疗组选用百会、大椎、脾俞、肾俞、命门、神阙、足三里、三阴交等穴,采用针刺和艾灸相结合的方法。两组均连续治疗6个月后,观察和比较患者临床症状积分和骨代谢的变化。结果:治疗6个月后两组血钙、血磷与治疗前比较均差异无统计学意义;两组Ⅰ型胶原羧基末端肽(β-Crosslaps)均较治疗前降低,腰椎和股骨颈骨密度及血清骨钙素(OPG)均较治疗前上升,治疗组改善更明显,与对照组比较差异有统计学意义(P<0.05)。两组患者症状积分均得到改善,治疗组较对照组下降更为明显(P<0.01)。结论:针灸结合阿仑膦酸钠能有效增加绝经后骨质疏松患者腰椎、股骨颈骨密度,改善患者症状积分,有较好的治疗效果。 相似文献
5.
目的观察鲑鱼降钙素和凯思立D治疗绝经后骨质疏松症的疗效。方法将128例绝经后骨质疏松症患者随机分为对照组和治疗组各64例,对照组口服凯思立D,1片/d;治疗组则在此基础上加用鲑鱼降钙素肌肉注射,50IU/次,1次/周,两组疗程均为6个月。治疗结束后,比较两组患者的疗效及不良反应情况。结果治疗组总有效率为92.2%,明显高于对照组53.1%,差异有统计学意义(P〈0.05);治疗组的骨密度较治疗前明显提高(P〈0.05),而对照组的骨密度则无明显变化,差异无统计学意义(P〉0.5)。结论鲑鱼降钙素联合凯思立D治疗绝经后骨质疏松症疗效好,可明显改善症状,增加骨密度。 相似文献
6.
目的:观察鲑鱼降钙素联合维D钙咀嚼片治疗绝经后骨质疏松性腰背痛的临床疗效及治疗前后骨密度变化。方法:应用鲑鱼降钙素及联合维D钙咀嚼片治疗261例绝经后骨质疏松患者腰背疼痛6个月,同期197例患者仅连续口服碳酸钙片及吲哚美辛片6个月做对照,观察两组治疗前后患者腰背部疼痛的改善情况(VAS 评分) 及腰椎、髋部骨密度变化。结果:鲑鱼降钙素治疗组VAS评分低于对照组(P〈0.05),且随治疗时间延长,VAS评分下降更加明显;腰椎及股骨颈骨密度增加高于对照组(P〈0.05)。结论:鲑鱼降钙素联合联合维D钙咀嚼片能明显改善绝经后骨质疏松性腰背痛。 相似文献
7.
目的探讨唑来膦酸注射液治疗绝经后骨质疏松症的临床疗效,评价其安全性。方法将绝经后骨质疏松症患者70例随机分成治疗组和对照组,各35例,两组在年龄、绝经年限等方面比较差异均无统计学意义(P〉0.05)。治疗组给予唑来膦酸注射液(密固达)5 mg/100 mL静滴1次,同时口服钙尔奇片。对照组仅给予口服钙尔奇片,两组受试者均连续服药10个月。观察骨痛、骨密度变化及安全性指标。结果治疗后治疗组骨痛症状明显缓解,两组总有效率比较差异有统计学意义(P〈0.05);骨密度检测治疗组增加与对照组比较差异有统计学意义(P〈0.05);治疗期间治疗组无新发骨折。结论唑来膦酸注射液对绝经后骨质疏松症患者具有缓解骨痛、增加骨密度、提高生活质量、减少骨折发生的作用,是一种有效、安全的药物。 相似文献
8.
目的探讨鳗鱼降钙素治疗绝经后骨质疏松症的疗效。方法将70例绝经后骨质疏松症患者随机分为两组,治疗组40例,应用鳗鱼降钙素治疗,20 IU肌注每周一次,疗程6个月;对照组30例。两组均口服钙尔奇D(含元素钙600 mg,维生素D125 IU)每天一片,疗程6个月。两组治疗前后均测定2-4腰椎、骨股颈及wards三角骨密度(bone mineral density,BMD),记录患者临床症状。结果治疗组2个月后骨痛改善率高于对照组(P〈0.01),治疗组患者腰2、腰3、腰椎均值BMD较前明显升高(P〈0.05)。对照组BMD治疗前后无明显变化(P〉0.05)。结论鳗鱼降钙素与钙剂联合应用对治疗绝经后骨质疏松症有减轻疼痛,改善症状,同时增加骨密度作用。 相似文献
9.
鳗鱼降钙素对绝经后骨质疏松症的疗效观察 总被引:1,自引:1,他引:0
目的 探讨鳗鱼降钙素治疗绝经后骨质疏松症的疗效.方法 将70例绝经后骨质疏松症患者随机分为两组,治疗组40例,应用鳗鱼降钙素治疗,20 IU肌注每周一次,疗程6个月;对照组30例.两组均口服钙尔奇D(含元素钙600 mg,维生素D125 IU)每天一片,疗程6个月.两组治疗前后均测定2~4腰椎、骨股颈及wards三角骨密度(bone mineral density,BMD),记录患者临床症状.结果 治疗组2个月后骨痛改善率高于对照组(P<0.01),治疗组患者腰2、腰3、腰椎均值BMD较前明显升高(P<0.05).对照组BMD治疗前后无明显变化(P>0.05).结论 鳗鱼降钙素与钙剂联合应用对治疗绝经后骨质疏松症有减轻疼痛,改善症状,同时增加骨密度作用. 相似文献
11.
不同剂量雌激素在绝经后骨质疏松症治疗中的作用 总被引:2,自引:0,他引:2
段定红 《复旦学报(医学版)》2003,30(5):477-479
目的 研究不同剂量雌激素对绝经后骨质疏松症的治疗作用。方法 6 9例绝经 <4年的妇女被随机分为 3组 (每组 2 3例 ) ,A组给予倍美力 0 .6 2 5mg +安宫黄体酮 2mg +钙尔奇D片 1g/d ;B组给予倍美力 0 .3mg +安宫黄体酮 2mg +钙尔奇D片 1g/d ;C组给予安慰剂 +钙尔奇D片 1g/d ;连续用药 2年。在用药前、用药后 6、12、2 4个月分别检测骨密度、骨代谢生化指标、骨细胞调节因子、子宫内膜增厚及乳房情况。结果 A组和B组在用药后一年骨密度有明显提高 ,而C组在一年后骨密度呈下降趋势。治疗组中均未发现子宫内膜的异常增生。骨代谢生化指标及血清IL 6水平在用药 6个月时就有显著下降。结论 在绝经早期的妇女中 ,小剂量雌激素加钙剂能防治骨质疏松症的发生 ,增加HRT(性激素替代疗法 )的安全性 ,降低子宫内膜过度增厚和阴道出血的发生率。此种雌激素加钙剂防治骨质疏松症的联合治疗方案值得推广。 相似文献
12.
13.
中医药不同剂型治疗绝经后骨质疏松症概况 总被引:1,自引:0,他引:1
李毅 《浙江中医药大学学报》2009,33(2):290-292
[目的]初步探讨绝经后骨质疏松症中医药不同剂型的治疗作用。[方法]查阅了1994年6月至2008年12月间与绝经后骨质疏松症的中医药治疗研究项目相关的文献167篇。[结果]与剂型密切相关文章61篇,其中胶囊、丸、片类27篇,散、颗粒、冲剂、饮、膏、汤、口服液类34篇。[结论]与临床分期治疗相结合,可将不同剂型分为二大类,一类为作用较快速但持续时间较短的汤水剂,适用于急性期;另一种为作用较缓慢的成形剂,适宜于慢性期。 相似文献
14.
Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis 总被引:2,自引:0,他引:2
Background Jaw osteonecrosis possibly associated with the administration of bisphosphonates is expected to be treated with a non-pharmacologic approach. This study aimed to determine whether noninvasive, mechanically mediated vibration would inhibit the decline in bone mineral density (BMD) that follows menopause, enhance the BMD of the lumbar and femoral neck, and reduce chronic back pain in postmenopausal women with osteoporosis.
Methods A total of 116 postmenopausal women with osteoporosis participated in this study, and they were divided into groups A (66 patients) and B (50). Group A received vibration treatment (Subjects vertically stand on the vibration platform, with a vibration frequency of 30 Hz, amplitude of 5 mm; they received the treatment five times per week, ten minutes each time and totally for six months), whereas women of group B served as controls without any treatment. L2-4 BMD, bilateral femoral neck BMD, and body mass index (BMI) were recorded before the treatment or at the third and sixth months of the treatment respectively. After the ending of the treatment, the change of BMD in each group was compared and analyzed. Chronic back pain was evaluated by visual analogue scale (VAS) at baseline and the third and sixth months of the treatment.
Results Of the 116 women, 94 including 51 women from group A ((61.23±8.20) years) and 43 women from group B ((63.73±5.45) years), completed the study. There were no significant differences in baseline characteristics including age, BMI, menopausal years, lumbar BMD, femoral neck BMD, and VAS between the two groups. The lumbar BMD of the 51 women in group A increased by 1.3% (P=0.034) after vibration treatment for 3 months and by 4.3% at the sixth month (P=0.000). The lumbar BMD in group B was decreased at the third month, but there was not statistical significance (P〉0.05) At the sixth month, it was decreased by 1.9% (P 〈0.05). The femoral neck BMD of the 51 women in group A was slightly in 相似文献
Methods A total of 116 postmenopausal women with osteoporosis participated in this study, and they were divided into groups A (66 patients) and B (50). Group A received vibration treatment (Subjects vertically stand on the vibration platform, with a vibration frequency of 30 Hz, amplitude of 5 mm; they received the treatment five times per week, ten minutes each time and totally for six months), whereas women of group B served as controls without any treatment. L2-4 BMD, bilateral femoral neck BMD, and body mass index (BMI) were recorded before the treatment or at the third and sixth months of the treatment respectively. After the ending of the treatment, the change of BMD in each group was compared and analyzed. Chronic back pain was evaluated by visual analogue scale (VAS) at baseline and the third and sixth months of the treatment.
Results Of the 116 women, 94 including 51 women from group A ((61.23±8.20) years) and 43 women from group B ((63.73±5.45) years), completed the study. There were no significant differences in baseline characteristics including age, BMI, menopausal years, lumbar BMD, femoral neck BMD, and VAS between the two groups. The lumbar BMD of the 51 women in group A increased by 1.3% (P=0.034) after vibration treatment for 3 months and by 4.3% at the sixth month (P=0.000). The lumbar BMD in group B was decreased at the third month, but there was not statistical significance (P〉0.05) At the sixth month, it was decreased by 1.9% (P 〈0.05). The femoral neck BMD of the 51 women in group A was slightly in 相似文献
15.
阿仑膦酸钠防治绝经后骨质疏松的疗效 总被引:1,自引:0,他引:1
目的观察国产阿仑膦酸钠防治绝经后骨质疏松症的疗效。方法56例50~74岁骨量减少或骨质疏松的绝经后妇女随机分为两组(每组28人),每日给予阿仑膦酸钠10mg/d或安慰剂,两组均加服碳酸钙片和维生素D,治疗6个月。试验前后用双能X线吸收法检测腰椎和髋部的骨矿密度(bonemineraldensity,BMD),同时检测骨转换的生化指标。结果与治疗前相比,治疗组腰椎BMD平均增加5%(P<0.01),对照组各部位的BMD均下降(P<0.05);治疗组骨吸收指标和骨形成指标均降低,其中NTx下降最明显,近75.7%(P<0.001),而对照组却无显著性变化。结论国产阿仑膦酸钠能降低绝经后妇女的骨转换,增加骨量。 相似文献
16.
目的:了解类风湿关节炎(rheumatoid arthritis ,RA)患者骨质疏松(osteoporosis ,OP)的发生情况,并探讨其相关影响因素。方法使用双能X线骨密度仪测量64例RA 患者的股骨颈、Ward’s三角区、大转子、腰椎骨密度(bone mineral density ,BMD),并予60例年龄、性别、体重指数匹配的健康志愿者作为对照组。结果 RA 组在腰椎(L2~ L4)、股骨上端(股骨颈、Ward’ s 三角区、大转子)的BMD较对照组均明显降低,差异有统计学意义(P<0.05)。结论 RA 患者普遍发生BMD下降,骨量减少和O P发病率均显著高于对照组,其发病机制可能与 RA 本身及糖皮质激素的长期应用等因素相关。 相似文献
17.
目的:探讨利塞膦酸钠治疗绝经后骨质疏松症的临床疗效,并评价其安全性。方法:54例绝经后骨质疏松症患者采取随机双盲、安慰剂平行对照方式进行12个月的药物研究,以双能量X线骨密度测量仪比较治疗前后0月,6个月,12个月腰椎及髋部骨密度(BMD)改变,检测骨代谢标志物血Ca、ALP、BGP及尿NTX在治疗前后的变化,并监测血尿常规、肝肾功能、心电图、X线等药物安全性指标,记录不良事件。结果:腰椎(L2-4)BMD增加6个月时增加3.29±1.18%,12个月时为4.51±1.64%而对照组分别为-0.62±0.24%和0.48±0.18%,股骨颈、大转子和wards三角区骨密度骨密度改变药物组和对照组无显著差异;反映骨形成标记物ALP和BGP6个月和12个月时药物组显著降低,骨吸收标记物NTx在6月和12月较治疗前显著降低(P<0.01)。主要不良反应为消化道反应2例(7.1%)、皮肤搔痒、皮疹2例(7.1%)和血尿1例(3.6%),均能缓解。结论:利塞膦酸钠治疗绝经后骨质疏松症有显著疗效,骨转换显著抑制,并显示该药物良好的安全性。 相似文献
18.
XU Xiao-juan SHEN Lin YANG Yan-ping LU Fu-rong ZHU Rui SHUAI Bo LI Cheng-gang WU Man-xiang 《中华医学杂志(英文版)》2013,126(13):2480-2484
Background Sclerostin, expressed exclusively by osteocytes, is a negative regulator of bone formation. To gain insights into the action of sclerostin in postmenopausal osteoporosis, we evaluated serum sclerostin levels in postmenopausal women and investigated its possible associations with bone turnover markers in patients with postmenopausal osteoporosis.
Methods We detected serum sclerostin, and measured lumbar spine bone mineral density in 650 Chinese postmenopausal women. We also assessed serum levels of β-isomerized C-terminal crosslinking of type I collagen, intact N-terminal propeptide of type I collagen, N-mid fragment of osteocalcin, 25-hydroxyvitamin D, and estradiol.
Results Serum sclerostin levels were lower in postmenopausal osteoporotic women compared with non-osteoporotic postmenopausal women ((38.79±7.43) vs. (52.86±6.69) pmol/L, P <0.001). Serum sclerostin was positively correlated with lumbar spine bone mineral density (r=0.391, P <0.001) and weakly negatively correlated with β-isomerized C-terminal crosslinking of type I collagen, intact N-terminal propeptide of type I collagen, N-mid fragment of osteocalcin (r= –0.225, P <0.001; r= –0.091, P=0.046; r= –0.108, P=0.018; respectively) in postmenopausal osteoporosis. There was no significant association of serum sclerostin with age, body mass index, 25-hydroxyvitamin D, and estradiol (r= –0.004, P=0.926; r=0.067, P=0.143; r=0.063, P=0.165; r= –0.045, P=0.324; respectively).
Conclusion Sclerostin may be involved in the pathogenesis of postmenopausal osteoporosis and may play a role in bone turnover.
相似文献
19.
With the aging of the population,the inci-dence of pri mary osteoporosis is getting higher andhigher,among which post menopausal osteoporosis(PMOP)is the most commontype.As an effectivemedicine to inhibit bone absorption,bisphospho-nates has become the main medicationtotreat oste-oporosis.In this clinical trial,we investigated theefficacy of residronate sodium,the third-generationbisphosphonates made in China,in the treat mentof PMOP by exploring its effect on bone mineraldensity(BMD)and b… 相似文献